Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue 8, 2005, Pages 761-768

  Allen, Holley F ^a   Mazzoni, Cristina ^a   Heptulla, Rubina A ^b   Murray, Mary A ^c   Miller, Nancy ^a   Koenigs, Laura ^a   Reiter, Edward O ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Adolescent; Metformin; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; ETHINYLESTRADIOL PLUS NORGESTIMATE; GLUCOSE; INSULIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; TESTOSTERONE;

ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; HUMAN; HYPERINSULINISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 24944480071     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2005.18.8.761     Document Type: Article

References (47)

1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191.
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
3. Franks S. Polycystic ovary syndrome. Arch Dis Child 1997; 77: 89-90.
4. Dramusic V, Rajan U, Chan P, Ratnam SS, Wong YC. Adolescent polycystic ovary syndrome. Ann NY Acad Sci 1997; 816: 194-208.
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169.
6. Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996; 65: 946-949.
7. Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. The Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific Publications, 1992.
8. Dunaif A, Scott D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299-3306.
9. Nestler JE, Jakubawicz DJ. Decreases in ovarian cytochrome P450c17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617-623.
10. Velaquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-654.
11. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.
12. Dunaif A, Segal KR, Shelley DR, Green G, Dobrajansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-1266.
13. Krowchuk DP, Stancin T, Keskinen R, Walker R, Bass J, Anglin TM. The psychosocial effects of acne on adolescents. Pediatr Dermatol 1991; 8: 332-338.
14. Trent M, Rich M, Austin M, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adoles Med 2002; 156: 556-560.
15. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 1997; 46: 454-457.
16. Velazquez EM, Acosta A, Mendoza S. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90: 392-395.
17. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovarian syndrome and their first degree relatives. J Clin Endocrinol Metab 2001; 86: 2027-2031.
18. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-530.
19. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85: 3526-3530.
20. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligoamenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adoles Health 2001; 29: 160-169.
21. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87: 1555-1559.
22. Trent M, Ludwig D. Adolescent obesity, a need for greater awareness and improved treatment. Curr Opin Pediatr 1999; 11: 297-302.
23. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815-825.
24. Allen BS, Smith GS Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982; 118: 23-25.
25. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694-2698.
26. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Urakawa H, Morioka K, Kitagawa N, Tanaka T, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y. QUICKI is useful for following improvements in insulin sensitivity after therapy in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 2906-2908.
27. Skrha J, Haas T, Sindelka G, Prazny M, Widimsky J, Cibula D, Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICK1 indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004; 89: 135-141.
28. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
29. Nestler JE, Jakubawicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876-1880.
30. Diamante-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138: 269-274.
31. Morin-Papunen LC, Koivuner RM, Ruokonen A, Martikainer HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 691-696.
32. Lee E. Statistical Methods for Survival Data Analysis, 2nd Ed. New York: Wiley, 1992; 374-378.
33. Rolland-Cachera M. Body composition during adolescence: methods, limitations and determinants. Horm Res 1993; 39: 25-40,
34. Dixon W. BMDP/Dynamic. BMDP Statistical Software, 1993.
35. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, eds. 2nd International Symposium on Information Theory and Control. Budapest: Akademia Kiado, 1973; 267-281.
36. Tukey JW. Some thoughts on clinical trials especially problems of multiplicity. Science 1977; 198: 679-684.
37. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457-1461.
38. Morin-Papner LC, Vauhkunen I, Koivuner RM, Ruokonen A, Martikainer HK, Tapanainer JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85: 3161-3168.
39. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
40. Lee A, Morley J. Metformin decreases food consumption and induces weight loss in subjects with obesity and type II non-insulin-dependent diabetes. Obes Res 1998; 6: 47-53.
41. Stumvoll M, Nurjihan N, Perriello G, Dailey G, Gerich J. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
42. Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997; 82: 3074-3077.
43. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 3327-3334.
44. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994; 61: 598-604.
45. Ibanez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, de Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 5702-5705.
46. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 1017-1023.
47. Knowler WC, Barrett-Conner E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.